We and others have demonstrated that rare tumors that originate in distinct anatomical sites are not uncommonly underpinned by highly recurrent somatic genetic alterations (e.g., adenoid cystic carcinomas, which are driven by the MYB-NFIB or MYBL1 rearrangements in the breast, salivary glands and the lungs)38,39. The gene discussed is MYBL1; the disease is adenoid cystic carcinoma.